🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Tomorrow at #AACR25 Dr. Marcelo Negrao will present in the poster session, data from a phase 2 cohort of KRYSTAL-1. Outcomes will be shared from first-line KRAS G12C inhibitor in patients with advanced #NSCLC harboring KRAS G12C and STK11 mutations. #LCSM #lungcancer

We're exploring the pathophysiology of #PulmonaryFibrosis, and the key role the lysophosphatidic acid (LPA-LPA1) pathway plays in fibrosis, inflammation, and epithelial injury, all of which result in disease progression at #ATS2025. Learn more: bit.ly/3GR5ICD #OneBMS

We aim to address the unmet needs of the billions of people worldwide living with neurological and neuropsychiatric conditions through agile neuroscience research. Explore how we’re working to bring patients new life-changing treatments: bit.ly/4jqT1N0 #APA2025 #OneBMS

Introducing DoctoRx Unscripted: Bold Conversations. Breakthrough Ideas. Patient-Driven Science. Rigorously scientific, peer-to-peer evidence-based conversations meant to ignite innovation and arm you with ideas to transform your own practice. bit.ly/3Fs3mJU

We’re sharing more than 80 abstracts and presentations exploring our latest data in oncology at #ASCO25. Be sure to also stop by our booth this week to check out our interactive “Grand Library” and learn more about our work in oncology here: bit.ly/3T25nzv #OneBMS

Now live: Episode 1 of #DoctoRxUnscripted - Rewiring Reality: Dr. Tania Small and Dr. John Kane on the Future of Schizophrenia Care. Unpack the science, challenge assumptions & explore breakthroughs in biology, early psychosis & patient-driven science. bit.ly/43zzNhD

Join us at #PsychCongressElevate2025 for a focused look into schizophrenia. Erin Crown, MHSPAS, PA-C, CAQ-Psychiatry, explores its syndromal nature and the role of multiple neurotransmitter pathways beyond dopamine in its pathophysiology.

Now live: Ep 2 of #DoctoRxUnscripted - Unlocking Minds, Rewriting Futures: Dr. Tania Small & Dr. Ilan Melnick on Forensic Psychiatry & True Rehabilitation. Explore the science of psychosis & the impact of a dignity-first approach to psychiatric treatment. bit.ly/3SojtLx

Our scientists, like Garima, are tackling cancer from all angles leveraging our differentiated research platforms, toolbox of modalities and advanced digital capabilities. See how we’re redefining #CancerResearch: bit.ly/3FoOIDj #ASCO25 #OneBMS

Tomorrow at #ASCO, Dr Martin Reck will present in the poster session in-depth biomarker analyses to elucidate the mechanisms underlying the clinical activity of front-line LAG-3 inhibition in combination with PD-1 inhibition and chemotherapy in metastatic NSCLC. #lungcancer

Antibody-drug conjugates (ADCs) are just one promising option in our toolbox of modalities being studied in cancer. Hear our Cambridge site head Emma Lees share how we’re collaborating to realize the potential of ADCs. Learn more: bit.ly/4mFykPp #ASCO25 #OneBMS

Tomorrow at #ASCO, hear a 1L KRAS G12C inhibitor + immunotherapy phase 2 update from KRYSTAL-7 in patients with advanced KRAS G12C-mutated NSCLC. Join us at the session tomorrow at 8:00 AM CDT in the Aire Crown Theater #LCSM #lungcancer

Today at #ASCO, join us in the plenary session for the phase 3 NIVOPOSTOP trial led by the GORTEC group, evaluating the addition of adjuvant PD-1 inhibition to SOC for patients with resected locally advanced squamous cell carcinoma of the head and neck at high risk for relapse.

Personalized treatments like #CARTcelltherapy have transformed the #multiplemyeloma landscape over the last few years. However, the disease remains relentless, so we are committed to delivering novel treatment approaches and will present data at #ASCO25. bit.ly/4mDYulL

Today at #ASCO, Dr Mariano Provencio will present updated survival and biomarker analyses of perioperative IO-based regimen in resectable NSCLC from CheckMate 77T. Join the session at 4:30 PM CDT in Hall D1. #LCSM #lungcancer

Tomorrow at #ASCO, hear Dr Kathryn C. Arbour present updated data from a Phase 1 clinical trial of BMS-986504, an MTA-cooperative PRMT5i, in patients with advanced solid tumors with homozygous MTAP deletion.

We’re committed to exploring novel cancer targets to combat advanced #solidtumors. Inhibiting PRMT5 may prevent tumor cells from growing and dividing, and we’re excited to present new data exploring this potential at this year’s #ASCO25.

Today at #ASCO, Dr Patrick Forde will present the final analysis of overall survival from the CheckMate 816 trial of neoadjuvant-only IO+chemo for patients with resectable NSCLC. Join us in the Arie Crown Theater at 3:00 PM CDT #LCSM #lungcancer

We support independent medical education (IME) programs that advance excellence in global healthcare through evidence-based medical education. Explore our IME programs in oncology: bit.ly/4jsT7mI #ASCO25

At #EHA2025, we’re supporting independent medical education (IME) programs that drive excellence in healthcare. Don’t miss our IME/CME events across disease areas including multiple myeloma, myelofibrosis and anemia, and classic Hodgkin lymphoma: bit.ly/4jN4E0f